Publikationen

Schönknecht P, Hunt A, Toro P, Guenther T, Henze M, Haberkorn U, Schröder J
Bihemispheric cerebral FDG PET correlates of cognitive dysfunction as assessed by the CERAD in Alzheimer's disease.
Clin EEG Neurosci 2011; 42(2): 71-76

Weber MA, Henze M, Tüttenberg J, Stieltjes B, Meissner M, Zimmer F, Burkholder I, Kroll A, Combs SE, Vogt-Schaden M, Giesel FL, Zoubaa S, Haberkorn U, Kauczor HU, Essig
Biopsy Targeting Gliomas: Do Functional Imaging Techniques Identify Similar Target Areas?
Invest Radiol 2010; 45(12): 755-768

Schönknecht P, Hunt A, Toro P, Henze M, Haberkorn U, Schröder J
Neural correlates of delayed episodic memory in patients with mild cognitive impairment - a FDG PET study.
Neurosci Lett. 2009; 467(2): 100-104

Henze M
Nuklearmedizinische Diagnostik
In: Diagnostic and Interventional Neuroradiology – A Multimodality Approach (Hrsg.: Jansen / Forsting / Sartor), Georg Thieme Verlag Stuttgart, New York 2008, 3. Auflage 2008

Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, Schilling T, Haufe S, Herrmann T, Haberkorn U
Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.
Eur J Nucl Med Mol Imaging 2007; 34 (10):1617-1626

Hunt A, Schönknecht P, Henze M, Seidl U, Haberkorn U, Schröder J
Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease
Psychiatry Res 2007; 155 (2): 147-154

Henze M, Özdemir-Sahin N, Hipp P, Mier W, Eisenhut M, Debus J, Haberkorn U
Comparison of the diagnostic accuracy of 18F-FDG PET, 123I-IMT- and 99mTc-MIBI SPECT. Evaluation of tumor progression in irradiated low grade astrocytomas
Nuklearmedizin 2006; 45: 49-56

Hunt A, Schönknecht P, Henze M, Toro P, Haberkorn U, Schröder J
CSF tau protein and FDG PET in patients with aging-associated cognitive decline and Alzheimer´s disease
Neuropsychiatric Disease and Treatment 2006; 2: 207-212

Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A, Haberkorn U, Debus J
Improved Target Volume Definition for Fractionated Stereotactic Radiotherapy in Patients with Intracranial Meningiomas by Correlation of CT, MRI and [68Ga]-DOTATOC PET
Int J Rad Oncol Biol Phys 2006; 65: 222-227

Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, Mäcke HR, Eisenhut M, Debus J, Haberkorn U
Characterization of [68Ga]-DOTA-D-PHE1 -TYR3 -Octreotide (DOTA-TOC) kinetics in patients with meningiomas
J Nucl Med 2005; 46: 763-769

Henze M
Chapter 1: Craniocerebral Diseases – Nuclear Medicine Imaging
In: Diagnostic and Interventional Neuroradiology – A Multimodality Approach (Editor: Sartor K), Georg Thieme Verlag Stuttgart, New York 2002, pp 35-40. 2nd Edition 2005

Henze M
Chapter 2: Spinal Diseases – Nuclear Medicine Imaging
In: Diagnostic and Interventional Neuroradiology – A Multimodality Approach (Editor: Sartor K), Georg Thieme Verlag Stuttgart, New York 2002, pp 277-280. 2nd Edition 2005

Henze M, Hipp P
Chapter 3.3: Imaging – Nuclear Medicine
In: 3D Conformal Radiation Therapy - Multimedia Introduction to Methods and Techniques (Editors: Schlegel W, Mahr A), Springer Verlag, Berlin, Heidelberg, New York 2001; 2nd Edition 2005

Schönknecht P, Pantel J, Hunt A, Henze M, Strowitzki T, Schröder J
Chapter 13: Estrogens in Alzheimer’s Disease: A Clinical and Neurobiological Perspective
In: Estrogene Effects in Psychiatric Disorders (Editors: Bergemann N, Riecher-Rössler A)
Springer Verlag Wien, New York, 2nd Edition 2005, pp 253-269.

Schuhmacher J, Zhang H, Doll J, Mäcke HR, Matys R, Hauser H, Henze M, Haberkorn U, Eisenhut M
GRP receptor-targeted PET imaging of a rat pancreas carcinoma xenograft in nude mice with a 68Ga labeled Bombesin [6-14] analog
J Nucl Med 2005; 46: 691-699

Henze M, Mohammed A, Schlemmer H, Herfarth K, Hoffner S, Haufe S, Mier W, Eisenhut M, Debus J, Haberkorn U
PET and SPECT in the detection of tumor progression in irradiated low grade astrocytomas:
An ROC analysis
J Nucl Med 2004; 45: 579-586

Hünerbein R,  Jäkel O,  Karger C,  Schulz-Ertner D.,  Fachbeiräte Henze M, Haberkorn U
Kapitel 6: Nuklearmedizin
In: Reiser M, Kuhn F-P, Debus J (Hrsg.) Radiologie, Thieme-Verlag Stuttgart, 2004, pp 140-147.

Henze M, Schuhmacher J, Dimitrakopoulou-Strauss A, Strauss LG, Mäcke HR, Eisenhut M, Haberkorn U
Exceptional Increase in Somatostatin Receptor Expression in Pancreatic Neuroendocrine Tumour, visualised with 68Ga-DOTATOC-PET
Eur J Nucl Med 2004; 31: 466

Dietz A, Rudat V, Harms W, Jungehülsing M, Dollner R, Henze M
Predictive value of 18F-FDG-PET in early detection of residual disease after larynx organ preserving chemoradiation
HNO 2004; 52: 38-44

Lichy MP, Bachert P, Henze M, Lichy CM, Debus J, Schlemmer HP
Monitoring individual response to brain-tumour chemotherapy: Proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy
Neuroradiology 2004; 46: 126-129

Lichy MP, Henze M, Plathow C, Bachert P, Kauczor HU, Schlemmer HP
Metabolic imaging to follow stereotactic radiation of gliomas - the role of 1H MR spectroscopy in comparison to FDG-PET and IMT-SPECT
RöFo 2004; 176: 1114-21

Doll J, Henze M, Bublitz, Werling A, Adam LE, Haberkorn U, Semmler W, Brix G
High resolution reconstruction of PET images using the iterative OSEM algorithm
Nuklearmedizin 2004; 43: 72-78

Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, Eberle AN
A gallium-labeled DOTA-α-Melanocyte stimulating hormone analog for PET imaging of melanoma metastases
J Nucl Med 2004; 45: 116-123

Schönknecht P, Henze M, Hunt A, Klinga K, Haberkorn U, Schröder J
Hippocampal glucose metabolism is associated with cerebrospinal fluid estrogen levels in postmenopausal women with Alzheimer’s disease
Psychiatry Res Neuroim 2003; 124(2): 125-127

Durani BK, Klein A, Henze M, Haberkorn U, Hartschuh W
Somatostatin Analogue Scintigraphy in Merkel Cell Tumours
Br J Dermatol 2003; 148: 1135-1140

Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Haberkorn U
Evaluation of PET Imaging using 68Ga-DOTA-D Phe1-Tyr3-Octreotide (DOTATOC) in comparison to 111In-DTPAOC (Octreoscan). First results in patients with neuroendocrine tumors.
Mol Imaging Biol 2003; 5: 42-48

Karger CP, Hipp P, Henze M, Echner G, Höss A, Schad L, Hartmann GH
Stereotactic imaging for radiotherapy: Accuracy of CT, MRI, PET and SPECT
Phys Med Biol  2003; 48: 211–221

Henze M, Mohammed A, Schlemmer H, Herfarth KK, Mier W, Eisenhut M, Debus J, Haberkorn U
Detection of tumor progression in the follow-up of irradiated low grade astrocytomas: Comparison of 3-[123I]-Iodo-Alpha-Methyl-L-Tyrosine and 99mTc-MIBI SPET
Eur J Nucl Med 2002; 29: 1455-1461

Henze M, Mohammed A, Mier W, Rudat V, Dietz A, Nollert J, Eisenhut M, Haberkorn U
Pretreatment Evaluation of the Hypopharynx and Larynx Carcinoma with 18F-fluorodeoxyglucose, 123I-α-methyl-tyrosine and 99mTc-hexakis-2-methoxyisobutylisonitrile
Eur J Nucl Med 2002; 29: 324-330

Gutschalk A, Kollmar R, Mohr A, Henze M, Ille N, Schwaninger M, Hartmann M, Hähnel S, Haberkorn U, Rupp A, Meyding-Lamade U
Multimodal functional imaging of prolonged neurological deficits in familial hemiplegic migraine
Neurosci Lett 2002; 332: 115-118

Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frölich L, Schönknecht P, Ito K, Mielke R, Kalbe E, Zündorf G, Delbuecke X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Beuthien-Baumann B, Menzel C, Schröder J, Kato T, Arahata Y, Henze M, Heiss WD
Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET
Neuroimage 2002; 17: 302-316

Schlemmer HP, Bachert P, Henze M, Buslei R, Herfarth KK, Debus J, van Kaick G
Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy
Neuroradiology 2002; 44: 216-222

Lichy MP, Henze M, Sammet S, Maudsley AA, Bachert P, Debus J, Schlemmer HP
Clinical decision making in irradiated gliomas: Value of Proton MR Spectroscopy compared to FDG-PET and IMT-SPECT
In: Proceedings of the 10th Scientific Meeting of the Int. Society for Magnetic Resonance in Medicine. Editor: International Society for Magnetic Resonance in Medicine. Honolulu, USA: ISMRM, 2002: 575.

Schlemmer HP, Lichy MP, Henze M, Sammet S, Maudsley AA, Debus J, Bachert P
Proton MR spectroscopy in irradiated brain tumors.
In: Proceedings of the 10th Scientific Meeting of the Int. Society for Magnetic Resonance in Medicine. Editor: International Society for Magnetic Resonance in Medicine. Honolulu, USA: ISMRM, 2002: 2040.

Martin SJ, Eisenbarth JA, Wagner-Utermann U, Mier W, Henze M, Pritzkow H, Haberkorn U, Eisenhut M
A new precursor for the radiosynthesis of [18F]FLT
Nucl Med Biol 2002; 29: 263-273

Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker D, Doll J, Mäcke H, Hofmann M, Debus J, Haberkorn U
PET Imaging of somatostatin receptors using [68Ga]-DOTA-D Phe1-Tyr3-Octreotide (DOTATOC): First results in meningioma-patients
J Nucl Med 2001; 42: 1053-1056

Henze M, Hittel J-P
Mucoepidermoid carcinomas of the salivary glands after high-dose radioiodine therapy
Laryngorhinootologie 2001; 80: 253-256

Hempel A, Henze M, Berghoff C, Garcia N, Ody R, Schröder J
PET findings and neuropsychological deficits in a case of Fahr's disease
Psychiatry Res Neuroim 2001; 108(2): 133-140

Schlemmer HP, Henze M, Herfarth K, Bachert P, Debus J, van Kaick G  
Proton MR spectroscopy and 18F-FDG-PET for the assessment of suspicious lesions after brain tumor radiotherapy
In: Proceedings of the 9th Scientific Meeting of the Int. Society for Magnetic Resonance in Medicine. Editor: International Society for Magnetic Resonance in Medicine. Glasgow.
ISMRM, 2001; 3: 2288

Brix G, Henze M, Knopp MV, Lucht R, Doll J, Junkermann H, Hawighorst H, Haberkorn U
Comparison of Pharmacokinetic MR and [18F]Fluorodeoxyglucose PET in the diagnosis of breast cancer: Initial experience
Eur Radiol 2001; 11: 2058-2070

Hofmann M, Maecke H, Börner AR, Weckesser E, Schöffski P, Oei ML, Schumacher J, Henze M, Heppeler A, Meyer GJ, Knapp WH
Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data.
Eur J Nucl Med 2001; 28:1751-1757

Haberkorn U, Altmann A, Kamencic H, Morr I, Traut U, Henze M, Jiang S, Metz J, Kinscherf R
Glucose transport and apoptosis after gene therapy with HSV thymidine kinase.
Eur J Nucl Med 2001; 28: 1690-1696

Schuhmacher J, Klivenyi G, Kaul S, Henze M, Matys R, Hauser H, Clorius J
Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET.
Nucl Med Biol 2001; 28: 821-828

Schuhmacher J, Kaul S, Klivenyi G, Junkermann H, Magener A, Henze M, Doll J, Haberkorn U, Amelung F, Bastert G
Immunoscintigraphy with Positron Emission Tomography: Gallium-68 Chelate Imaging of Breast Cancer Pretargeted with Bispecific Anti-MUC1/Anti-Ga Chelate Antibodies
Cancer Res 2001; 61: 3712-3717

Haberkorn U, Henze M, Altmann A, Jiang S, Morr I, Mahmut M, Peschke P, Kübler W, Debus J, Eisenhut M
Transfer of the human sodium iodine symporter gene enhances iodine uptake in hepatoma cells
J Nucl Med 2001; 42: 317-325

Brix G, Henze M, Doll J, Lucht R, Zaers J, Trojan H, Knopp MV, Haberkorn U
Diagnostic evaluation of the breast using PET: Optimization of data acquisition and postprocessing
Nuklearmed 2000; 39: 62-66

Wodarski C, Eisenbarth J, Weber K, Henze M, Haberkorn U, Eisenhut M
Synthesis of 3'-deoxy-3'-[18F]fluoro-thymidine with 2,3´-O-anhydro-5´-O-(4,4´-dimethoxytrityl)-thymidine.
J Labelled Cpd Radiopharm 2000; 43: 1211-1218

Henze M, Hittel J-P, Elser H
Mucoepidermoid carcinoma of the submandibular gland after high-dose radioiodine therapy: Case report and review of the literature
Nuklearmed 1998; 37: 38-42

Elser H, Henze M, Hermann C, Eckert W, Mende U
99mTc-MIBI for recurrent and metastatic differentiated thyroid carcinoma
Nuklearmed 1997; 36: 7-12

Elser H, Henze M, Spierer FJ, Georgi P
Semiquantitative 99mTc-HMPAO SPECT in dementia of the Alzheimer type: Influence of the selection of reconstruction filter and reference region
Nuklearmed 1996; 35: 243-50